The spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), coupled
with a lack of therapeutics or vaccines, has paralyzed the globe. While significant effort has …

The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
coupled with a lack of therapeutics, has paralyzed the globe. Although significant effort has …

The use of passively-administered neutralizing antibodies is a promising approach for the
prevention and treatment of SARS-CoV-2 infection. Antibody-mediated protection may …

The current global COVID-19 pandemic caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) has resulted in a public health crisis with more than 168 million …

Although SARS-CoV-2-neutralizing antibodies are promising therapeutics against COVID-
19, little is known about their mechanism (s) of action or effective dosing windows. We report …

Monoclonal antibody (mAb) therapies have rapidly become a powerful class of therapeutics
with applications covering a diverse range of clinical indications. Though most widely used …

Neutralizing antibodies are known to have a crucial role in protecting against SARS-CoV-2
infection and have been suggested to be a useful correlate of protection for vaccine clinical …

The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) pandemic has caused
more than 676 million cases in the global human population with approximately 7 million …

Major efforts were deployed to study the antibody response against SARS-CoV-2.
Antibodies neutralizing SARS-CoV-2 have been extensively studied in the context of …

Monoclonal antibodies (mAbs) with neutralizing activity against SARS-CoV-2 have
demonstrated clinical benefit in cases of mild to moderate SARS-CoV-2 infection …